Related Experiment Video
Updated: Nov 20, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs
Ashok K Vaid1, Alok Gupta2, Gagandeep Momi3
1Department of Medical Oncology, Medanta Cancer Institute, Gurugram, Haryana 122001, India.
Abstract:
A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma (NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic target in NSCLC. Treatment strategies for patients with advanced‑stage NSCLC have markedly changed, from the empirical use of cytotoxic agents to targeted regimens. EGFR tyrosine kinase inhibitors (TKIs), the first‑line therapy for advanced NSCLC, are reported to be the most effective. Although progression‑free survival (PFS) and objective response rates have long been used as endpoints, meeting these endpoints may not necessarily coincide with an increase in overall survival (OS) among patients with advanced lung cancer. Recently, the FLAURA study with the third‑generation, irreversible, oral EGFR‑TKI, osimertinib, demonstrated an extended median OS by 6.8 months compared with standard EGFR‑TKIs, with a 20% reduction in the risk of mortality [osimertinib, 38.6; EGFR‑TKIs, 31.8; hazard ratio (HR), 0.80; 95% confidence interval (CI), 0.641‑0.997; P=0.046]; this was in addition to meeting the primary endpoint of clinically and statistically significant PFS. Osimertinib was also shown to lead to a statistically significant reduction in the risk of central nervous system disease progression (HR, 0.48; 95% CI, 0.26‑0.86; P=0.014). Notably, 28% of patients remained on osimertinib treatment for 3 years, considerably longer than those in the comparator group (9%). The duration of first subsequent treatment with osimertinib was 25.5 months compared with 13.7 months with standard EGFR‑TKIs (HR, 0.478; 95% CI, 0.393‑0.581; P<0.0001). Thus, the long‑term OS benefit with first‑line osimertinib highlights a promising option in the management of stage IV NSCLC. The present narrative review compares the OS benefit of first‑, second‑ and third‑generation EGFR‑TKIs for patients with stage IV EGFR mutation‑positive NSCLC and discusses their role in disease management.
Insights
First-line osimertinib significantly improves overall survival in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. This third-generation EGFR tyrosine kinase inhibitor (TKI) offers a promising therapeutic option, extending survival and reducing mortality risk.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Non-small cell lung carcinoma (NSCLC) frequently harbors epidermal growth factor receptor (EGFR) mutations, representing a key therapeutic target.
- Treatment paradigms for advanced NSCLC have shifted from chemotherapy to targeted therapies, particularly EGFR tyrosine kinase inhibitors (TKIs).
Purpose of the Study:
- To compare the overall survival (OS) benefit of first-, second-, and third-generation EGFR-TKIs in patients with stage IV EGFR mutation-positive NSCLC.
- To evaluate the role of osimertinib as a first-line treatment option for advanced NSCLC.
Main Methods:
- This narrative review analyzes data from clinical studies, focusing on overall survival (OS), progression-free survival (PFS), and central nervous system disease progression.
- Comparison of outcomes between third-generation EGFR-TKI (osimertinib) and standard EGFR-TKIs in first-line treatment for advanced NSCLC.
Main Results:
- Osimertinib demonstrated a significant extension in median OS by 6.8 months compared to standard EGFR-TKIs (38.6 vs. 31.8 months), with a 20% reduction in mortality risk.
- Osimertinib significantly reduced the risk of central nervous system disease progression (HR, 0.48) and showed a longer duration of first subsequent treatment (25.5 vs. 13.7 months).
- A higher proportion of patients (28%) remained on osimertinib for 3 years compared to the comparator group (9%).
Conclusions:
- First-line osimertinib provides a substantial long-term overall survival benefit for patients with stage IV EGFR mutation-positive NSCLC.
- Osimertinib represents a promising and effective therapeutic option in the management of advanced NSCLC, improving survival and disease control.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023